NCT04318938已完成2 期
Advancing Brigatinib Properties in Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer (ALK+ NSCLC) Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest42 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2020年3月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 118
- 试验地点
- 42
- 主要终点
- Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1
研究概览
简要总结
This is a prospective, randomized, open-label, multicenter phase II study investigating the advancing Brigatinib properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping
详细描述
The aim of this study is to compare efficacy of brigatinib and other 2nd-generation ALK tyrosin kinase inhibitor (TKI) in 1st and 2nd line treatment and to explore resistance patterns according to treatment and molecular properties of the tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully informed written consent and any locally-required authorization (EU Data Privacy Directive) given by the patient
- •Male or female ≥ 18 years of age NOTE: There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
- •Histologically confirmed locally advanced (stage III) and not suitable for curative treatment, i.e. R0 operation or definitive chemo-/radiation, or metastatic (stage IV) ALK+ NSCLC NOTE: Documentation of ALK rearrangement by a positive result of any ALK assay approved in Germany [i.e. positivity for at least one of the three: immunohistochemistry (IHC), NGS, fluorescence in situ hybridisation (FISH)] must be available at baseline. Treatment can already be started based on a local ALK+ test result, but subsequent central testing of the baseline biopsy for molecular profiling, incl. determination of ALK variant and TP53 status, should be made possible for all patients.
- •No prior therapy for metastatic ALK+ NSCLC including therapy with ALK inhibitors. However, 1 or 2 cycles of chemotherapy, chemo-immunotherapy or immunotherapy as well as cerebral irradiation before inclusion in the study will be allowed.
- •At least 1 measurable (i.e., target) lesion per RECIST v1.1 or otherwise evaluable lesion (e.g. brain lesion with at least 5 mm of longest diameter if measured by high-resolution cMRT e.g. using 1 mm slices thickness and not planned for irradiation before the first response assessment).
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Have adequate organ function, as determined by:
- •Total bilirubin ≤1.5x the upper limit of the normal range (ULN) (< 3x the ULN if Gilbert's disease is present)
- •Estimated glomerular filtration rate ≥30 mL/minute/1.73 m2 (calculated by Modification of Diet in Renal Disease (MDRD) or any other validated formula, see Appendix 13.4)
- •Alanine aminotransferase/aspartate aminotransferase ≤2.5x ULN NOTE: ≤5x ULN is acceptable if liver metastases are present.
- •Serum lipase or serum amylase ≤ 1.5x ULN
- •Platelet count ≥75x 109/L
- •Hemoglobin ≥9 g/dL
- •Absolute neutrophil count ≥1.5x 109/L
- •Willingness and ability to comply with scheduled visit and study procedures
- •Patient willing to participate in accompanying research program
- •Collection of current biopsy during screening must be feasible NOTE: For each patient a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block must be available for biomarker evaluation. Excisional, incisional or core needle biopsies are appropriate, while fine needle aspirations are insufficient.
- •Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to randomization. Women must not be breastfeeding.
- •Female patients who:
- •are postmenopausal for at least 1 year before the screening visit, OR
- •are surgically sterile, OR
- •if they are of childbearing potential, agree to practice highly effective non-hormonal contraception from the time of signing the informed consent through at least 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
- •Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:
- •agree to practice effective barrier contraception during the entire study treatment period and through at least 3 months after the last dose of study drug, OR
- •agree to completely abstain from heterosexual intercourse.
排除标准
- •History or presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis
- •Uncontrolled hypertension, defined as hypertension treated* with anti-hypertensive drugs AND blood pressure ≥ 160 mmHg (systolic) or ≥ 100 mmHg (diastolic) in repeated measurements. Untreated elevated blood pressure is not an exclusion criterion and should receive adequate anti-hypertensive adjustment.
- •*Please notecase of treatment, at least 3 anti-hypertensive drugs should have been used with the intention to control hypertensive disease
- •Systemic treatment with strong cytochrome P-450 (CYP) 3A inhibitors, strong CYP3A inducers, or moderate CYP3A inducers or treatment with any investigational systemic anticancer agents, chemotherapy or radiation therapy (except for stereotactic radiosurgery or stereotactic radiation therapy or palliative radiotherapy) within 14 days of randomization
- •Treatment with antineoplastic monoclonal antibodies within 30 days of randomization
- •Major surgery within 30 days of randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsies, are allowed.
- •Current symptomatic spinal cord compression as confirmed by radiographic imaging. Patients with leptomeningeal disease without symptomatic cord compression are allowed.
- •Significant or uncontrolled cardiovascular disease, defined as to the following:
- •If an acute myocardial infarction has ensued in the past 6 months, successful reperfusion has to be documented and the patient has to be free of symptoms
- •New York Heart Association Class III or IV heart failure (i.e. marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest) within 6 months prior to randomization
- •Any history of clinically significant ventricular arrhythmia, defined as ventricular tachycardia (VT), ventricular fibrillation (VF), or cardiac arrest
- •Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug
- •Malabsorption syndrome or other gastrointestinal illness or condition that could affect oral absorption of the study drug
- •Active severe or uncontrolled chronic infection, including but not limited to, the requirement for intravenous antibiotics for longer than 2 weeks
- •History of HIV infection. Testing is not required in the absence of history.
- •Chronic hepatitis B (surface antigen-positive) or chronic active hepatitis C infection. Testing is not required in the absence of history.
- •Any serious medical condition or psychiatric illness that could, in the investigator's opinion, potentially compromise patient safety or interfere with the completion of treatment according to this protocol
- •Known or suspected hypersensitivity to brigatinib or other TKI or their excipients
- •Life-threatening illness unrelated to cancer
- •Involvement in the planning and/or conduct of the study (applies to both Takeda staff and/or staff of sponsor and study site)
- •Patient who might be dependent on the sponsor, site or the investigator
- •Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities [according to national Medicinal Products Act (Arzneimittelgesetz, AMG)]
- •Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [according to national AMG]
- •Legal incapacity or limited legal capacity
- •Females who are pregnant or breastfeeding
- •Patients who have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.
- •NOTE: If a patient has worsening neurological symptoms or signs due to CNS metastasis, the patient needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days prior to randomization.
- •Rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
研究组 & 干预措施
Standard Arm with any available ALK TKI
Active Comparator
- st line: Any approved 2nd-generation TKI according to investigator's choice
- nd line: Any available ALK TKI according to investigator's choice (patients from the standard Arm A can be offered brigatinib in the 2nd line)
干预措施: Tyrosine kinase inhibitor (Drug)
Experimental Arm with Brigatinib
Experimental
- st line: 90 mg brigatinib once daily p.o. for the first 7 days (lead-in) followed by 180 mg brigatinib once daily p.o. afterwards, starting with day 8
- nd line: Any available ALK TKI according to investigator's choice
干预措施: Brigatinib (Drug)
结局指标
主要结局
Progression-free survival (PFS) of 1st-line treatment according to RECIST v1.1
时间窗: 68 months
Time from the first dosing date of any study medication to the date of the first objectively documented tumor progression or death due to any cause
次要结局
- PFS of 2nd-line treatment according to RECIST v1.1(68 months)
- Overall survival (OS)(68 months)
- Intracranial DOR (iDOR) according to RECIST v1.1(68 months)
- Quality of life (QoL) assessed by SF-12-questionnaire(68 months)
- Quality of life (QoL) assessed by EORTC-quality of life questionnaire (QLQ)-BN20-questionnaire(68 months)
- TNT 1st line (TNT1, i.e. time-to-next treatment for the 1st line)(68 months)
- TNT 2nd line (TNT2, i.e. time-to-next treatment for the 2nd line(68 months)
- TNT1/2 (time-to-next treatment for the 1st and 2nd line together)(68 months)
- Intracranial ORR (iORR)(68 months)
- Time to intracranial progression (TTiP)(68 months)
- Safety (rate of adverse events)(68 months)
研究者
研究点 (42)
Loading locations...
相似试验
进行中（未招募）
1 期
Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotypingAnaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001828-36-DEInstitut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest116
已完成
2 期
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibALK-positive Advanced NSCLCNCT03535740Ariad Pharmaceuticals103
撤回
2 期
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaAnaplastic Large Cell Lymphoma, ALK-PositiveNCT03719898Fox Chase Cancer Center
招募中
2 期
Phase II Study of Brigatinib for ALK-positive advanced non-small cell lung cancer with brain metastasesALK-positive advanced non-small cell lung cancer with brain metastasesnon-small cell lung cancerJPRN-jRCTs071230025aoki Katsuhiko22
终止
2 期
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNeoplasmsPancreatic NeoplasmsOvarian NeoplasmsBrain NeoplasmsThyroid NeoplasmsNeuroendocrine TumorsSalivary Gland NeoplasmsHead and Neck NeoplasmsThyroid Cancer, PapillaryLymphoma, Large-Cell, AnaplasticNeoplasms by SiteRespiratory Tract NeoplasmsThoracic NeoplasmsRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsMelanomaDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesCentral Nervous SystemSarcomaColorectal NeoplasmsCholangiocarcinomaNCT04644315Hoffmann-La Roche1